{"id":"inm-176","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3644560","moleculeType":"Small molecule","molecularWeight":"431.39"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, INM-176 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"INM-176 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:16.854Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06600698","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2025-05-07","conditions":"Prostate Cancer","enrollment":45},{"nctId":"NCT05375539","phase":"PHASE1","title":"AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2023-05-02","conditions":"Prostate Cancer","enrollment":12},{"nctId":"NCT01245530","phase":"PHASE3","title":"An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia","status":"COMPLETED","sponsor":"Whanin Pharmaceutical Company","startDate":"2008-06","conditions":"Alzheimer Type Dementia","enrollment":280}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["KR-WAP-026"],"phase":"phase_3","status":"active","brandName":"INM-176","genericName":"INM-176","companyName":"Whanin Pharmaceutical Company","companyId":"whanin-pharmaceutical-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"INM-176 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}